Pharmaceuticals in Europe industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry.

This management report critically analyzes the changing market conditions and the impact of these opportunities on the generics industry and multinational R&D companies.

The global economic downturn and equity market decline since the late 1990s badly affected the entire financial services industry and resulted in dramatic cuts in IT spending.

This exciting intelligence CD-ROM on European biotech industry has become better, stronger and more intelligent in its 5th Edition.

Many prescribers rely on websites provided by pharmaceutical companies when searching for treatment information. Consumers also rely heavily on online resources when searching for disease and treatment information. Websites that tailor their site conte

The number of product information sites provided to consumers in the EU is limited, while disease and public education sites are abundant and are used to effectively target consumers, and sites targeting healthcare professionals in the EU are readily a

The value of CME is widely recognized in both the US and Europe. Even so, the approaches these two regions have taken with regard to the regulation, provision and funding of CME activities vary considerably. Therefore, pharmaceutical companies must tak

Time constraints are limiting the amount of time that physicians and consumers spend to search for information, as well as the amount of time that pharmaceutical companies have to access physicians. As a result, the importance of pharmaceutical website

The number of patients eligible for cardiovascular therapies is increasing quickly, and, as in the developed pharmaceutical markets, is primarily driven by increases in prevalence in diabetes and obesity, trends that do not appear likely to diminish ov

The countries of the Eastern European region feature a range of diverse healthcare systems, but can be divided into two categories, those of the EU accession countries which feature the strongest prospects for growth in pharmaceutical sales, and those

This report examines the actions taken by legislative and regulatory bodies in response to recent drug safety concerns surrounding the COX-2 inhibitors and antidepressants.

Analyzes parallel trade market dynamics, reviews the latest regulatory and pricing controls in the EU and US, and assesses the drivers and resistors of parallel trade in 2004.

This report is a comprehensive source of market analysis of the most valuable therapy area within the global pharmaceutical market; Valued at an estimated $73.7bn in 2002, the global market for cardiovascular drugs grew by a moderate 2.5% over 2001 lev

The coming year will be one of immense change for the pharmaceutical industry in Europe. The continued development of the eEconomy is critical to the continued growth and success of the European pharmaceutical market. Companies that implement forward-l

Successfully managing the lifecycle of molecules within marketed portfolios is an essential capability for the pharma industry. With R&D productivity stalling, and profit margins increasingly eroded by cost containment initiatives, maximizing the retur

Due to the restrictions on direct-to-consumer advertising in Europe, pharmaceutical companies need to find an effective way to provide information to European consumers. The availability of physician-targeted websites is also more limited in Europe and

Build a business development function that wins key deals. This report features qualitative and quantitative findings from 22 different companies that range from the industry’s top ten to up-and-coming biotechs.

Since the beginning of this decade, parallel trade levels of pharmaceutical drugs in the US and Europe have risen to some of the highest levels ever seen, exerting additional pressure on the profitability of pharmaceutical companies. As a result, it ha

Use this latest report to determine key product opportunities, identify potential alliance partners and plan a successful and sustainable long term growth strategy to secure your leading position in the next five years.